Literature DB >> 2863337

Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons.

L A Chiodo, B S Bunney.   

Abstract

Extracellular single-cell recording techniques were employed to study the mechanism of action of repeated oral clozapine administration on the in vivo spontaneous activity of substantia nigra (A9) and ventral tegmental area (A10) dopamine (DA)-containing neurons in the rat. Clozapine was observed to affect DA neurons differentially within these two regions when compared to haloperidol. Acute treatment (1 hr) with both drugs increased the number of spontaneously firing neurons in both A9 and A10. Chronic (21 day) treatment with haloperidol decreased the number of cells encountered in both regions, whereas repeated treatment with clozapine reduced the number of DA cells per track only in A10. In all cases, the silent DA neurons were inferred to be in a state of depolarization inactivation since they could be induced to discharge normally by the microiontophoretic application of the inhibitory neurotransmitter gamma-aminobutyric acid. These effects were not due to an effect of chloral hydrate anesthesia since they were also observed in gallamine-paralyzed, artificially respired animals. Chronic co-administration with haloperidol of either an anticholinergic (trihexyphenidyl) or the alpha 1-norepinephrine (NE) receptor antagonist, prazosin, but not an alpha 2-NE antagonist, RX781094, resulted in a differential effect on A9 and A10 DA neurons identical to that observed with repeated clozapine administration alone. Thus, chronic treatment with these combinations of drugs resulted in the depolarization inactivation of only A10 cells. These data suggest that anticholinergic and/or alpha 1-NE-blocking properties of clozapine may, in part, mediate its differential effects on A9 and A10 midbrain DA neurons.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863337      PMCID: PMC6565310     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

1.  Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2006-08-30       Impact factor: 4.530

Review 2.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Repeated SKF 38393 and nigrostriatal system neuronal responsiveness: functional down-regulation is followed by up-regulation after withdrawal.

Authors:  M D Kelland; D K Pitts; A S Freeman; L A Chiodo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

Review 4.  Do neuroleptic drugs still have a place in neurological therapy?

Authors:  T Klockgether; J Dichgans
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

Review 5.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

Authors:  C J Bench; A A Lammertsma; P M Grasby; R J Dolan; S J Warrington; M Boyce; K P Gunn; L Y Brannick; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

7.  Seroquel: electrophysiological profile of a potential atypical antipsychotic.

Authors:  J M Goldstein; L C Litwin; E B Sutton; J B Malick
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat.

Authors:  E L Gardner; L S Walker; W Paredes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm.

Authors:  Min Feng; Nan Sui; Ming Li
Journal:  Behav Brain Res       Date:  2012-10-23       Impact factor: 3.332

10.  Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.

Authors:  R Rivest; C A Marsden
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.